Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes and obesity, is now being used widely in patients with type 2 diabetes. Real-world data continue to be gathered, which need close observation in this rapidly developing and exciting management option. 

Using the US Food and Drug Administration Adverse Event Reporting System database, Zhang and colleagues evaluated adverse events reported with tirzepatide. A disproportionality analysis was conducted on reports from May 2022 to the fourth quarter of 2024. The majority of significant adverse events included expected issues, such as gastrointestinal (nausea and diarrhoea) and injection site-related events. Known risks such as pancreatitis and hypoglycaemia were confirmed. Some unexpected adverse events included post-menopausal bleeding and upper respiratory tract infections.

This analysis is consistent with gastrointestinal and pancreatic risks of tirzepatide known from prior clinical studies, and identifies potential new safety concerns, underscoring the need for vigilant monitoring, particularly during initial treatment phases.

A wide audience of individuals working with patients who have type 2 diabetes and obesity will find this article enlightening.

Read the full article in Endocrine Connections 14 e25020 https://doi.org/10.1530/EC-25-0205